BioTek awarded patent for Hybrid Technology in multimode microplate readers
BioTek has been awarded US patent 8,218,141 covering the combination of two alternate paths for light within the same analytical instrument. Known as Hybrid Technology, the patented functionality is available in BioTek’s Synergy NEO HTS Multi-Mode Microplate Reader and in the Synergy H4 and H1 Hybrid Multi-Mode Microplate Readers.
Using Hybrid Technology, light can be directed to and from the microplate samples through a filter-based optical system or through a monochromator-based optical system for wavelength selection. This two-optical-path system provides optimal performance and flexibility for a wide range of applications in fluorescence microplate assays. The company’s Synergy readers are modular platforms that can include fluorescence intensity, UV-Vis absorbance, luminescence, TRF, TR-FRET and FP detection modes.
BioTek instrumentation is used to aid in the advancement of life science research, facilitate the drug discovery process, provide rapid and cost-effective industrial analysis and to enable sensitive and accurate quantification of a wide range of molecules across diverse applications.
Blood-based biomarker can detect sleep deprivation
The biomarker detected whether individuals had been awake for 24 hours with a 99.2% probability...
Epigenetic signature helps to diagnose rare breast tumour
The current way of diagnosing phyllodes tumours is to analyse their cellular features under a...
New instrument measures cardiovascular disease biomarkers
CVD-21 enables a 'liquid cardiovascular biopsy' for quantification of multiple...
